Loading
A phase 3 trial of pembrolizumab in lung cancer, run by UNICANCER, active but no longer recruiting.
PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT03774732 by UNICANCER, with a registry enrolment figure of 327 participants, started 2018-01-24 and due to reach its primary completion in 2026-12-22. Interventions recorded: Radiotherapy; Pembrolizumab; Chemotherapy. Conditions listed: Non Small Cell Lung Cancer; Non Small Cell Lung Cancer Metastatic; Non-Small Cell Carcinoma of Lung, TNM Stage 4. Primary outcome: 1-year Overall Survival. Lung eligibility wording from the registry: "Histologically or cytologically confirmed advanced (stage IIIB/IIIC/IV), squamous or non-squamous NSCLC". Sites: France, Monaco. No results are recorded here; the registry entry is the source.
Shares Lung cancer trials open today (registry snapshot), Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), IMRT / IGRT (modern external beam), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), IMRT / IGRT (modern external beam), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), IMRT / IGRT (modern external beam), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), IMRT / IGRT (modern external beam), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), IMRT / IGRT (modern external beam), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag lung-deep-dive.